Business ❯ Finance ❯ Investments

Pharmaceuticals

Eli Lilly Novo Nordisk Stock Market Acquisitions Pfizer Clinical Trials Drug Development Indian Pharma Stocks Stock Performance Biotechnology Novo Nordisk A/S Tariffs Generic Drugs Market Trends Johnson & Johnson Market Analysis Mergers and Acquisitions Market Competition Eli Lilly and Company Generic Medicines Bristol Myers Squibb Innovative Drugs Biosimilars AbbVie Weight Loss Drugs Teva Pharmaceutical Industries Drug Pricing Weight-loss Drugs Market Reactions Drug Distribution Stock Analysis AstraZeneca PLC Merck & Co. BioMarin Pharmaceutical Inc. Animal Research Company Performance Bristol-Myers Squibb Company Regeneron Pharmaceuticals BioCryst Pharmaceuticals Specialty Pharmacy Clinical Research Royalty Pharma Commercial Alliances Partnerships Vertex Pharmaceuticals Roche Holding Moderna Biopharmaceuticals Sun Pharma Wockhardt Ltd. Knight Therapeutics Inc. Biotech Companies Company Valuation Drug Performance Earnings Reports Aurinia Pharmaceuticals Sales Forecasts Cannabinoids Balaxi Pharmaceuticals Psychedelic Drugs Dr Reddy's Laboratories Agios Pharmaceuticals Biohaven Mankind Pharma Indian Pharma Drug Approval Telix Pharmaceuticals Biopharmaceutical Companies Biotech Vanda Pharmaceuticals Novartis Sun Pharmaceuticals AstraZeneca Indian Pharma Companies Telix Pharmaceuticals Ltd. Telehealth Fennec Pharmaceuticals TauRx Pharmaceuticals Drug Companies Amneal Pharmaceuticals Innoviva, Inc. Psychoactive Compounds Licensing Deals Gilead Sciences Psilocybin Company Growth Biopharma Teva Pharmaceutical Industries Limited Cancer Drug Licensing HIV Treatments Cohance Lifescience Radiopharmaceuticals

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

The clearance allows private prescribing in Britain while routine NHS access waits on a national cost‑effectiveness review.

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Wall Street Unanimously Bullish on Teva as Austedo Fuels Turnaround

Eli Lilly's GLP‑1 Surge Leaves Pfizer as the High‑Yield Option

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Cardinal Health Lifts 2026 Profit Outlook After Q3 Beat Despite Sales Miss

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Amneal to Acquire Kashiv BioSciences to Expand in Biosimilars

Law Firms Seek Ultragenyx Investors to Lead Securities Class Actions After OI Trial Miss

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views